美国制药巨头辉瑞（Pfizer）已与减肥药新贵Metsera公司签署收购协议，在与丹麦药企诺和诺德（Novo Nordisk）的竞购战中胜出。后者正是减肥药Ozempic和Wegovy的制造商。
Metsera总部位于纽约，目前尚无产品上市，但正在研发口服与注射类药物，其中部分新型疗法有望切入利润可观的肥胖症与糖尿病治疗领域。
这笔交易表明，尽管数月前辉瑞终止了一款口服减肥药的研发，但其仍在积极布局相关领域。
Metsera公司在上周五发布的声明中表示，辉瑞将以每股最高86.25美元的价格进行收购，其中包括每股65.60美元的现金支付，以及一份或有价值权利，持有人未来可获得每股最高20.65美元现金。
Metsera在声明中指出，诺和诺德的收购方案存在美国反垄断风险。公司董事会认为，辉瑞修订后的收购条款“在交易价值与成交确定性方面，均代表了对股东最有利的选择”。
在这笔交易达成三天前，诺和诺德一度加码，在周二宣布将报价提高至最高100亿美元，试图在竞购战中击败辉瑞。此前，诺和诺德90亿美元的收购报价，曾引发辉瑞提起诉讼。
Metsera还表示，辉瑞也调整了9月提出的近49亿美元报价方案，增加了初始现金支付比例。
总部位于纽约的辉瑞通过邮件表示，对交易条款“非常满意”，并预计将在11月13日Metsera股东大会后尽快完成交易。
诺和诺德于上周六回应称，不会再提高报价，并宣布退出对Metsera的收购竞争。
根据其最新方案，诺和诺德原计划以每股62.20美元现金收购Metsera股份，高于此前每股56.50美元的报价，并承诺在达到特定研发与监管里程碑后，再支付每股24美元的或有价值权利。（*）
译者：刘进龙
审校：汪皓
美国制药巨头辉瑞（Pfizer）已与减肥药新贵Metsera公司签署收购协议，在与丹麦药企诺和诺德（Novo Nordisk）的竞购战中胜出。后者正是减肥药Ozempic和Wegovy的制造商。
Metsera总部位于纽约，目前尚无产品上市，但正在研发口服与注射类药物，其中部分新型疗法有望切入利润可观的肥胖症与糖尿病治疗领域。
这笔交易表明，尽管数月前辉瑞终止了一款口服减肥药的研发，但其仍在积极布局相关领域。
Metsera公司在上周五发布的声明中表示，辉瑞将以每股最高86.25美元的价格进行收购，其中包括每股65.60美元的现金支付，以及一份或有价值权利，持有人未来可获得每股最高20.65美元现金。
Metsera在声明中指出，诺和诺德的收购方案存在美国反垄断风险。公司董事会认为，辉瑞修订后的收购条款“在交易价值与成交确定性方面，均代表了对股东最有利的选择”。
在这笔交易达成三天前，诺和诺德一度加码，在周二宣布将报价提高至最高100亿美元，试图在竞购战中击败辉瑞。此前，诺和诺德90亿美元的收购报价，曾引发辉瑞提起诉讼。
Metsera还表示，辉瑞也调整了9月提出的近49亿美元报价方案，增加了初始现金支付比例。
总部位于纽约的辉瑞通过邮件表示，对交易条款“非常满意”，并预计将在11月13日Metsera股东大会后尽快完成交易。
诺和诺德于上周六回应称，不会再提高报价，并宣布退出对Metsera的收购竞争。
根据其最新方案，诺和诺德原计划以每股62.20美元现金收购Metsera股份，高于此前每股56.50美元的报价，并承诺在达到特定研发与监管里程碑后，再支付每股24美元的或有价值权利。（*）
译者：刘进龙
审校：汪皓
U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss treatments Ozempic and Wegovy.
Metsera, based in New York, has no products on the market, but it is developing oral and injectable treatments. That includes some potential treatments that could target lucrative fields for obesity and diabetes.
The deal comes as Pfizer is attempting to develop its own stake in that market, several months after ending development of a potential pill treatment for obesity.
In a statement issued Friday, Metsera said Pfizer will acquire the company for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value right entitling holders to additional payments of up to $20.65 per share in cash.
Metsera cited U.S. antitrust risks in Novo’s bid, saying in its statement that the board has determined Pfizer’s revised terms represent “the best transaction for shareholders, both from the perspective of value and certainty of closing.”
The deal comes three days after Novo Nordisk raised the stakes in its push to outbid Pfizer, saying Tuesday it would offer to pay as much as $10 billion for Metsera. That was higher than its previous bid of up to $9 billion which sparked a lawsuit from Pfizer.
Pfizer had also altered the offer it made in September of nearly $4.9 billion to provide more cash up front, Metsera had said.
New York-based Pfizer said in an email that it was happy with the terms of the deal, and expects to close the transaction shortly following the Metsera shareholder meeting on Nov. 13.
Novo Nordisk said Saturday it would not increase its offer and would leave the race to acquire Metsera.
Novo’s proposed deal had involved paying $62.20 in cash for each Metsera share, up from its previous bid of $56.50. The Danish drugmaker planned to tack on a contingent value right payment of $24, another improvement from its previous bid, if certain development and regulatory milestones were met.